TTPH - Tetraphase Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.1600
-0.1000 (-4.42%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close2.2600
Open2.2000
Bid2.1100 x 1100
Ask2.1600 x 2900
Day's Range2.0100 - 2.2138
52 Week Range0.5600 - 17.6000
Volume486,244
Avg. Volume1,666,039
Market Cap15.689M
Beta (5Y Monthly)2.05
PE Ratio (TTM)N/A
EPS (TTM)-13.3070
Earnings DateAug 06, 2020 - Aug 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Tetraphase Announces Second Amendment to Merger Agreement with AcelRx Pharmaceuticals for Increased Consideration
    Business Wire

    Tetraphase Announces Second Amendment to Merger Agreement with AcelRx Pharmaceuticals for Increased Consideration

    Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections, today announced that it has entered into a second amendment to the Agreement and Plan of Merger, dated March 15, 2020, asamended on May 27, 2020, to which the Company is a party with AcelRx Pharmaceuticals, Inc. ("AcelRx") and its merger subsidiary (the "Merger Agreement"), to increase the consideration payable to Tetraphase shareholders.

  • AcelRx Pharmaceuticals Announces Revised Merger Agreement with Tetraphase
    PR Newswire

    AcelRx Pharmaceuticals Announces Revised Merger Agreement with Tetraphase

    AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the execution of an amendment to its merger agreement to acquire Tetraphase Pharmaceuticals, Inc. (Tetraphase) (NASDAQ: TTPH), with revised consideration of $37.0 million in stock and cash based on the AcelRx closing share price on May 28, 2020, plus up to $16.0 million in contingent value rights (CVRs) payable in cash.

  • The Daily Biotech Pulse: PhaseBio To Start Potential Pivotal COVID-19 Trial, Immunomedics CEO Quits, Tetraphase Receives Sweetened Offer
    Benzinga

    The Daily Biotech Pulse: PhaseBio To Start Potential Pivotal COVID-19 Trial, Immunomedics CEO Quits, Tetraphase Receives Sweetened Offer

    Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 27) * ADC Therapeutics SA (NYSE: ADCT) (went public May 15) * Aeglea Bio Therapeutics Inc (NASDAQ: AGLE) * argenx SE - ADR (NASDAQ: ARGX) * ChemoCentryx Inc (NASDAQ: CCXI) * Imara Inc NASDAQ: (IMRA) * Immunovant Inc (NASDAQ: IMVT) * Mersana Therapeutics Inc (NASDAQ: MRSN) (announced positive interim Phase 1 data for XMT-1536 in patients with ovarian cancer) * Vermillion, Inc. (NASDAQ: VRML)Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 27) * Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) (announced publication of positive data for its antibiotic in treating bacteremia and endocarditis) * Sonnet Biotherapeutics Holdings Inc (NASDAQ: SONN) * Teligent Inc (NEW JERSEY) (NASDAQ: TLGT)Stocks In Focus PhaseBio Gets FDA Nod For Potentially Pivotal Trial Of COVID-19 Treatment PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) announced FDA authorization to proceed with VANGARD, a potentially pivotal clinical trial to evaluate PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome.PhaseBio said it expects to begin dosing patients by the end of June and report trial results late in the fourth quarter of 2020.The stock was jumping 54.3% to $6.82 in Thursday's premarket session.Roche To Commence Late-Stage Study Of COVID-19 Combo Treatment Option With Gilead's Remdesivir Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY) announced the initiation of a global Phase 3 study to evaluate the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir versus placebo plus remdesivir in hospitalized patients with severe COVID-19 pneumonia, in collaboration with Gilead Sciences, Inc. (NASDAQ: GILD).Roche aid it expects to enroll patients in the study in June, with the results likely to be available in the summer.Separately, Roche announced European approval of a new, shorter 2-hour Ocrevus infusion time, dosed twice yearly, for relapsing or primary progressive multiple sclerosis.Tetraphase Receives Sweetened Offer From Melinta After AcelRx's Revised Offer Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) said its board has received a revised proposal from Melinta amending its prior acquisition proposal. In light of the amended offer, Tetrephase said the Melinta offer is a superior offer.Tetraphase said it has notified AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) of the amended Melinta proposal, the superior offer determination and its intention to consider changing its recommendation or terminating the AcelRx offer unless AcelRx proposes revisions to the terms on or prior to Monday, June 1.This follows AccelRx sweetening its earlier offer to $30 million in stock and cash based on the AcelRx closing share price on May 22, plus an additional $14.5 million in contingent value rights payable in cash. See also: The Week Ahead In Biotech: ASCO Presentations In The Spotlight Aerpio To Collaborate With Quantum Leap In COVID-19 Drug Trial Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) and Quantum Leap Healthcare announced an agreement to evaluate razuprotafib in a new randomized, investigational treatment arm in the I-SPY COVID Trial for the treatment of ARDS in adult patients with moderate-to-severe COVID-19.The stock jumped 38.11% to $1.08 in after-hours trading.I-Mab's Severe COVID-19 Treatment Candidate Found Safe, Well-Tolerated In Phase 1b/2 Study I-Mab ADR (NASDAQ: IMAB) announced interim results from a clinical study of TJM2 in patients with cytokine release syndrome associated with severe COVID-19, with the Part 1 portion of the study evaluating the safety and tolerability of TJM2 in a total of 24 patients who were randomized at a ratio of 1:1:1 to receive either a single dose of 3 mg/kg TJM2, a single dose of 6 mg/kg TJM2 or placebo, administered by intravenous infusion.The company noted that a Data Monitoring Committee that evaluated data from Part 1 of the study concluded that it can commence the Part 2 of the study as planned, indicating TJM2 is safe and well-tolerated in the severe COVID-19 patients.The stock added 3.01% to $24.98 in after-hours trading.New Immunomedics CEO Quits Due To Coronavirus-Related Logistics Issues Immunomedics, Inc. (NASDAQ: IMMU) said CEO Harout Semerjian has decided to step down from his role effective immediately. Semeriian assumed the CEO role April 16 after his predecessor quit in the wake of a CRL for the company's lead antibody-drug conjugate sacituzumab govitecan and accusations regarding a data integrity breach.View more earnings on IBBThe company said the move was precipitated by the unfortunate significant logistical obstacles presented by the COVID-19 pandemic, including Semerjian's ability to fully assume his duties as CEO.Dr. Behzad Aghazadeh, executive chairman of Immunomedics, will continue to support the in an executive leadership role going forward, the company said.The stock was down 1.96% to $33.50 in the premarket session. FDA Grants Moleculin's Pre-IND Meeting Request For Coronavirus Drug Candidate, Shares to Resume TradingMoleculin Biotech, Inc., (NASDAQ: MBRX) said the FDA has granted the company's request for a pre-IND meeting to provide guidance regarding its plan to study its drug candidate WP1122 in a clinical trial for patients with COVID-19.The company said it plans to submit its IND application in the second half of the year, contingent on the guidance received from its pre-IND meeting with the FDA.Moleculin said in a separate release that Nasdaq has said its shares, which have been halted since May 4 due to questions regarding accuracy of information in the marketplace about its drug candidate for coronavirus, will begin trading again Thursday.Offerings Iovance Biotherapeutics Inc (NASDAQ: IOVA) said it intends to offer $500 million of its common stock, subject to market and other conditions, in an underwritten public offering. All of the shares in the offering are to be sold by the company.The stock was down 12.05% to $33.50 in Thursday's premarket session.BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) priced its underwritten public offering of 18.71 million shares at $4.50 per share. The company also said it is offering to certain investors pre-funded warrants to purchase up to an aggregate of 3.51 million shares of its common stock at $4.49 per pre-funded warrant.The company expects to raise gross proceeds of $100 million from the offering.The stock was down 7.25% at $4.67 premarket. Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) said it intends to offer in an underwritten public offering and subject to market and other conditions, $250 million worth of its common stock. All of the shares are being offered by the company.Arena shares were down 12.45% at $50.90 premarket. Arcus Biosciences Inc (NYSE: RCUS) said it has commenced an underwritten public offering of its common stock. All the shares in the offering will be sold by the company.The stock was down 1.29% at $26.70 premarket Thursday.On The Radar Earnings * Adverum Biotechnologies Inc (NASDAQ: ADVM) (after the close) * Geron Corporation (NASDAQ: GERN) (after the close)Related Link: Merck's Coronavirus Plan Of Attack: 2 Partnerships, M&A Deal Aimed At Treatment, Vaccine Development See more from Benzinga * The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Tetraphase Announces Receipt of Amended Melinta Proposal, Determination of Superior Offer and Notice to AcelRx
    Business Wire

    Tetraphase Announces Receipt of Amended Melinta Proposal, Determination of Superior Offer and Notice to AcelRx

    Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections, today announced that its Board of Directors has received a revised proposal from Melinta Therapeutics, Inc. ("Melinta") amending its prior proposal to acquire the Company (the "Amended Melinta Proposal"), and has determined that the Amended Melinta Proposal is a "Superior Offer" under the terms of the Agreement and Plan of Merger, dated March 15, 2020 and amended on May 27, 2020, to which the Company is a party with AcelRx Pharmaceuticals, Inc. ("AcelRx") and its merger subsidiary (the "AcelRx Merger Agreement"). In connection with this determination and in accordance with the terms of the AcelRx Merger Agreement, the Company has given notice to AcelRx of the Amended Melinta Proosal, the Superior Offer determination and of its intention to consider changing its recommendation of the AcelRx Merger Agreement or terminating the AcelRx Merger Agreement unless AcelRx proposes revisions to the terms of the AcelRx Merger Agreement or makes another proposal on or prior to Monday, June 1, 2020 that, if accepted, would result in the Amended Melinta Proposal ceasing to be a Superior Offer.

  • Tetraphase Announces Amendment to Merger Agreement with AcelRx Pharmaceuticals for Increased Consideration
    Business Wire

    Tetraphase Announces Amendment to Merger Agreement with AcelRx Pharmaceuticals for Increased Consideration

    Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ (eravacycline for injection) to treat serious and life-threatening infections, today announced that it has entered into an amendment to the Agreement and Plan of Merger, dated March 15, 2020, to which the Company is a party with AcelRx Pharmaceuticals, Inc. ("AcelRx") and its merger subsidiary (the "Merger Agreement"), to increase the consideration payable to Tetraphase shareholders.

  • The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray
    Benzinga

    The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray

    Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 21) * ADC Therapeutics SA (NYSE: ADCT) (IPOed May 15) * Allogene Therapeutics Inc (NASDAQ: ALLO) * AstraZeneca plc (NYSE: AZN) ( announced $1 billion BARDA funding for coronavirus vaccine program) * Biondvax Pharmaceuticals Ltd - ADR (NASDAQ: BVXV) * Cellectis SA (NASDAQ: CLLS) * ChemoCentryx Inc (NASDAQ: CCXI) * Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) * Cue Biopharma Inc (NASDAQ: CUE) * Fate Therapeutics Inc (NASDAQ: FATE) * Harpoon Therapeutics Inc (NASDAQ: HARP) * Horizon Therapeutics PLC (NASDAQ: HZNP) * Intellia Therapeutics Inc (NASDAQ: NTLA) * Kamada Ltd. (NASDAQ: KMDA) * Minerva Neurosciences Inc (NASDAQ: NERV) * Ovid Therapeutics Inc (NASDAQ: OVID) * Passage Bio Inc (NASDAQ: PASG)(FDA granted Rare Pediatric Disease designation to its gene therapy PBGM01 broadly for the treatment of GM1 gangliosidosis) * Soleno Therapeutics Inc (NASDAQ: SLNO) * Surface Oncology Inc (NASDAQ: SURF)Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 21) * Akorn, Inc. (NASDAQ: AKRX) (filed for Chapter 11 bankruptcy) * Digirad Corporation (NASDAQ: DRAD) * Genfit SA (NASDAQ: GNFT)Related Link: These 6 Coronavirus Vaccine Candidates Are The Likeliest To Succeed, Says Morgan StanleyStocks In Focus Aquestive's Partnered Parkinson's Drug Gets FDA Nod Aquestive Therapeutics Inc's (NASDAQ: AQST) development partner Sunovion announced FDA approval for Kynmobi sublingual film - APL-130277 - for the acute, intermittent treatment of OFF episodes in patients with Parkinson's disease. The drug is expected to be available in the U.S. pharmacies in September.Following the approval, Aquestive said it plans to monetize its PharmFilm based therapies."We continue to expect that we will receive between $50 to $100 million of non-dilutive capital from the monetization, in one or a series of transactions," the company said.The stock rose 5.2% to $6.47 in after-hours trading.Syndax's Lead Breast Cancer Drug Flunks Late-stage Study Syndax Pharmaceuticals Inc (NASDAQ: SNDX) said a late-stage study that evaluated its investigational compound entinostat along with exemestane in patients with HR+, HER2- breast cancer who have progressed on a non-steroidal aromatase inhibitor did not achieve the primary endpoint of demonstrating a statistically significant overall survival benefit over hormone therapy alone.The study was conducted by ECOG-ACRIN Cancer Research Group and sponsored by the National Cancer Institute.The stock slumped 19.41% to $16.52 in after-hours trading.Tiziana To Spin-off Its Personalized Medicines Businesses TIZIANA LF SCIE/S ADR (NASDAQ: TLSA) said it intends to demerge its StemPrintER and SPARE genomics-based personalized medicine businesses into a separate company and effect a capital reduction to facilitate the spin-out and listing of StemPrintER as an independent entity.Amarin To Support Pilot Study Of Vascepa In Treating COVID-19 Amarin Corporation plc (NASDAQ: AMRN) said it supports a clinical trial to investigate the effects of its Vascepa on inflammatory biomarkers and other patient outcomes in individuals with COVID-19. The trial is sponsored by the Canadian Medical and Surgical Knowledge Translation Research Group, the company said.Separately, generic pharma company Hikma Pharmaceuticals announced its wholly-owned U.S. subsidiary Hikma Pharmaceuticals USA Inc. has received FDA approval for its generic equivalent to Vascepa.In pre-market trading Friday, Amarin stock was adding 3.85% to $7.56.Navidea Reports Positive Mid-stage Results For Rheumatoid Arthritis Treatment Navidea Biopharmaceuticals Inc (NYSE: NAVB) announced positive preliminary results from the second interim analysis of its ongoing NAV3-31 Phase 2B study"Analysis demonstrates that these interim data further corroborate Navidea's hypotheses that Tc99m tilmanocept imaging can provide robust, quantitative imaging in healthy controls and in patients with active rheumatoid arthritis, and that this imaging can provide an early indicator of treatment efficacy in patients with active RA," the company said.The stock was seen skyrocketing 65.35% to $2.10 in pre-market trading.Roche Buys Gene Sequencing Tech Company Roche Holdings AG (OTC: RHHBY) announced acquisition of Stratos Genomics, an early-stage sequencing technology company to advance the development of its nanopore sequencer.The company did not disclose the financial terms of the dealTetraphase Deems Melinta's Latest All-Cash Offer As Superior, Notifies AcelRx Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH), which has been pursued by multiple companies, said its board has determined that the latest proposal from Melinta Therapeutics, Inc. is a "Superior Offer."'Melinta has offered $27 million in cash, plus an additional $12.5 million in cash potentially payable under contingent value rights to be issued in the proposed acquisition.View more earnings on IBBTetraphase, which agreed to a deal to be bought byAcelRx Pharmaceuticals Inc (NASDAQ: ACRX), said it has informed about its determination concerning the Melinta offer and given AcelRx time until May 29 to either terminate the merger or revise the terms of the merger.Incidentally, La Jolla Pharmaceutical Company (NASDAQ: LJPC) had also tabled an offer for Tetraphase.In pre-market trading, AcelRx shares were adding 2.74% to $1.50.Amag Divests Intrarosa For Upto $125M AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) said it has completed the sale of its rights to Intrarosa to Millicent Pharma Limited, for up to $125 million, including upfront fixed consideration of $20 million and contingent, sales-based milestone payments of up to $105 million.The company said the sale is consistent with its previously announced strategic decision to divest its women's health assets. It also said it remains committed to the divestiture of Vyleesi and associated expense reductions as previously announced.Offerings ContraFect Corp Stock (NASDAQ: CFRX) said it has priced its underwritten public offering of 11.8 million shares of its common stock and related warrants to purchase 8.85 million shares. The gross proceeds from the public offering will be approximately $52.5 million, it said. All shares in the public offering are to be sold by ContraFect.In premarket trading Friday, the stock was slipping 11.87% to $4.75.Hoth Therapeutics Inc (NASDAQ: HOTH) priced its underwritten public offering of 1.82 million shares of common stock at $2.75 per share, for raising gross proceeds of $5 million. The offering is expected to close on or about May 27.The stock was slipping 5.36% to $3 in premarket trading Friday.Dynavax Technologies Corporation (NASDAQ: DVAX) priced its previously announced underwritten public offering of 14 million shares of its common stock at $5 per share. The gross proceeds to Dynavax from the offering are expected to be approximately $70. The offering is expected to close on or about May 27.The stock was retreating 10.25% to $5.08 in premarket trading Friday.PPD Inc (NASDAQ: PPD) said it upsized and finalized the terms of the offering of $500 million aggregate principal amount of 4.625% senior notes due 2025 and $700 million aggregate principal amount 5.000% senior notes due 2028. The aggregate principal amount of the notes to be issued in the offering was increased to $1.2 billion from the previously announced $700 million, the company said.In premarket trading Friday, the stock was adding 1.23% to $28.Geron Corporation (NASDAQ: GERN) said it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock in an underwritten public offering. All the securities earmarked for the offering are being sold by the company.The stock was slipping 20.92% to $1.55 in pre-market trading.On The Radar Clinical Readouts Atara Biotherapeutics Inc's (NASDAQ: ATRA) abstract on the Phase 1 data for ATA188 in multiple sclerosis, regarding its European Academy for Neurology presentation, will be made available online at 12:30 pm ET.Earnings Teligent Inc (NEW JERSEY) (NASDAQ: TLGT)IPO Inari Medical, a medical device company, priced its upsized initial public offering of 8.203 million shares of its common stock at $19.00 per share, for total gross proceeds of approximately $156 million. The company had earlier planned for a 7.33-million stock offering, with an estimated price of $17-$18 per share. The shares are to be listed on the Nasdaq under the ticker symbol NARI.See more from Benzinga * The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive * The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test * The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces .34B Common Stock Offering(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Business Wire

    Tetraphase Announces Determination of Superior Offer and Notice to AcelRx

    Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline Xerava™ (eravacycline for injection) to treat serious and life-threatening infections, today announced that its Board of Directors has determined that the latest proposal from Melinta Therapeutics, Inc. ("Melinta") to acquire the Company is a "Superior Offer" under the terms of the Agreement and Plan of Merger, dated March 15, 2020, to which the Company is a party with AcelRx Pharmaceuticals, Inc. ("AcelRx") and its merger subsidiary (the "AcelRx Merger Agreement"). In connection with this determination and in accordance with the terms of the AcelRx Merger Agreement, the Company has given notice to AcelRx of such determination and of its intention to consider changing its recommendation of the AcelRx Merger Agreement or terminating the AcelRx Merger Agreement unless AcelRx proposes revisions to the terms of the AcelRx Merger Agreement or makes another proposal on or prior to Friday, May 29, 2020 that, if accepted, would result in the Melinta proposal ceasing to be a Superior Offer.

  • Catalyst (CPRX) Q1 Earnings Beat Estimates, Revenues Miss
    Zacks

    Catalyst (CPRX) Q1 Earnings Beat Estimates, Revenues Miss

    Catalyst (CPRX) beats on Q1 earnings but misses on revenues. It also withdraws sales guidance due to the coronavirus pandemic.

  • Tetraphase Pharmaceuticals (TTPH) Reports Q1 Loss, Lags Revenue Estimates
    Zacks

    Tetraphase Pharmaceuticals (TTPH) Reports Q1 Loss, Lags Revenue Estimates

    Tetraphase (TTPH) delivered earnings and revenue surprises of 19.63% and -28.37%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    Tetraphase Pharmaceuticals Reports First Quarter 2020 Financial Results and Highlights Recent Corporate Developments

    Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA to treat serious and life-threatening infections, today reported financial results for the first quarter ended March 31, 2020.

  • Bidding War Sends Tetraphase Shares Soaring
    Benzinga

    Bidding War Sends Tetraphase Shares Soaring

    Shares of nano-cap Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH), which have never really recovered from a steep sell-off triggered by an adverse clinical readout in late 2015, are surging Thursday after a second bidder emerged.Two-way Race The Watertown, Massachusetts-based company, which has a commercial antibiotic called Xerava to treat serious and life-threatening infections, is being pursued by La Jolla Pharmaceutical Company (NASDAQ: LJPC) after it signed a definitive agreement to be acquired by AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) in mid-March.La Jolla revealed in a filing it submitted a non-binding offer to acquire 100% of the equity of Tetraphase in an all-cash transaction.La Jolla offered for Tetraphase $22 million in cash, plus an additional $12.5 million potentially payable under contingent value rights, or CVRs, to be issued in the transaction.A contingent value right is a derivative instrument, with its value depending on some future event. If the event occurs by the specified date, then a holder of the CVR will get a pre-determined payout, mostly in cash."We are impressed with the growth potential of XERAVA and excited about the potential benefits of combining two companies focused on delivering important therapies to patients in the ICU," said Kevin Tang, Chairman of La Jolla in a letter addressed to the board of Tetraphase.Xerava, which was approved in August 2018, fetched Tetraphase revenues of $3.6 million in 2019 and $1.46 million in the fourth quarter of 2019.La Jolla said it plans to finance the proposed transaction with its cash on hand.Related Link: Attention Biotech Investors: Mark Your Calendar For These May PDUFA DatesAbout three weeks back, Tetraphase announced a definitive merger with AcelRx in a stock-for-stock transaction. The agreement provided for Tetraphase shareholders receiving 0.6303 share of AcelRx stock for each share they hold in Tetraphase, and a CVR, which will give the holders the right to receive aggregate payments of up to $12.5 million on achievement of future Xerava net sales milestones starting in 2021.The stock exchange ratio suggested valuation of $14.4 million at the close of trading March 13, a day before the deal was made public.AcelRx had said then it expects the deal to close in the second quarter. The boards of both companies vetted the transaction and certain stock and warrant holders holding an aggregate of approximately 31% of Tetraphase stock voting in favor of the deal.Merits Of The Offers La Jolla's superior cash offer cash might seem attractive at this juncture, as the world navigates through one of the worst crises it has ever faced."In our view, La Jolla's offer to Tetraphase hinges on an approximate $2.0M up-front premium to AcelRx's offer," H.C. Wainwright analyst Ed Arce said in a note. Despite La Jolla's higher consideration, he said Tetraphase might stick with the AcelRx offer.The terms of CVRs offered by both companies are same, except that La Jolla's CVRs would be paid in cash instead of cash or stock at the acquirer's option."We do not believe La Jolla's unsolicited competing bid is sufficiently compelling to Tetraphase to pull the company away from the current proposed transaction, especially given the amount of commitment and pre-close integration with AcelRx to date," Arce wrote in the note.The TTPH Move Tetraphase was up 89% to $2.63 at time of publication.Latest Ratings for TTPH DateFirmActionFromTo Mar 2020Gabelli & Co.DowngradesHoldSell Jan 2020Gabelli & Co.DowngradesBuyHold Oct 2019Gabelli & Co.UpgradesHoldBuy View More Analyst Ratings for TTPH View the Latest Analyst Ratings See more from Benzinga * The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test * The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Will Tetraphase Pharmaceuticals (TTPH) Report Negative Q1 Earnings? What You Should Know
    Zacks

    Will Tetraphase Pharmaceuticals (TTPH) Report Negative Q1 Earnings? What You Should Know

    Tetraphase (TTPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    SHAREHOLDER ALERT: WeissLaw LLP Reminds ETFC, TCO, TERP, and TTPH Shareholders About Its Ongoing Investigations

    NEW YORK, May 05, 2020 -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice.

  • Tetraphase (TTPH) to Post Q1 Earnings: What's in the Cards?
    Zacks

    Tetraphase (TTPH) to Post Q1 Earnings: What's in the Cards?

    During Tetraphase's (TTPH) upcoming Q1 earnings call, investor focus will be on management's update on the company's pending merger with AcelRx Pharmaceuticals.

  • GlobeNewswire

    Lifshitz Law Firm, P.C. Announces Investigation of CenterState Bank Corporation (CSFL), resTORbio, Inc. (TORC), Tetraphase Pharmaceuticals, Inc. (TTPH), and The Meet Group, Inc. (MEET)

    NEW YORK, April 30, 2020 -- CenterState Bank Corporation (CSFL) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with.

  • ACCESSWIRE

    Rigrodsky & Long, P.A. Files Class Action Suit Against Tetraphase Pharmaceuticals, Inc.

    WILMINGTON, DE, / ACCESSWIRE / April 29, 2020 / Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District Court for the District of Delaware on behalf of ...

  • GlobeNewswire

    SHAREHOLDER ALERT: WeissLaw LLP Reminds TTPH, TERP, LM, and ETFC Shareholders About Its Ongoing Investigations

    NEW YORK, April 28, 2020 -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this.

  • GlobeNewswire

    TTPH, FSB, FG, and OPB SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers

    WILMINGTON, Del., April 27, 2020 -- Rigrodsky & Long, P.A. announces that it is investigating: Tetraphase Pharmaceuticals, Inc. (NASDAQ GS: TTPH) regarding possible.

  • ACCESSWIRE

    INVESTOR ALERT: Halper Sadeh LLP Investigates the Sale of These Companies; Are Shareholders Getting a Fair Deal? - WLTW, TTPH, TERP

    NEW YORK, NY / ACCESSWIRE / April 21, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders. Halper Sadeh ...

  • GlobeNewswire

    SHAREHOLDER ALERT: WeissLaw LLP Reminds LM, TERP, and TTPH Shareholders About Its Ongoing Investigations

    NEW YORK, April 21, 2020 -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice.

  • ACCESSWIRE

    SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Sale of These Companies; Are Shareholders Getting a Fair Deal? - FG, OPB, TTPH

    NEW YORK, NY / ACCESSWIRE / April 21, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders. Halper Sadeh ...

  • GlobeNewswire

    NTGN, ETFC, TTPH, and MINI SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers

    WILMINGTON, Del., April 21, 2020 -- Rigrodsky & Long, P.A. announces that it is investigating: Neon Therapeutics, Inc. (NASDAQ GS: NTGN) regarding possible breaches of.

  • SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers; Are Shareholders Getting a Fair Deal?
    PR Newswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers; Are Shareholders Getting a Fair Deal?

    Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders:

  • GlobeNewswire

    SHAREHOLDER ALERT: WeissLaw LLP Reminds XPER, TIVO, and TTPH Shareholders About Its Ongoing Investigations

    WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Xperi Corporation (XPER) and TiVo Corporation (TIVO) in connection with the proposed merger of the two companies. Under the terms of the merger agreement, the shares of XPER and TIVO stockholders will be converted into shares of a new parent company based on a fixed exchange ratio of 0.455 XPER share per existing TIVO share.

  • ACCESSWIRE

    IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Sale of These Companies - WLTW, TTPH, TERP

    NEW YORK, NY / ACCESSWIRE / April 14, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders. Halper Sadeh ...